SAGE Therapeutics Inc. (SAGE) announced Monday morning that the positive safety and tolerability results for its Phase 2 study of SAGE-217 supports the company's plan to proceed to a double-blind, placebo-controlled Phase 2 trial.
from RTT - Before the Bell http://ift.tt/2lbKa7Y
via IFTTT
No comments:
Post a Comment